GraniteShares Advisors’s Biogen BIIB Stock Holding History

GraniteShares Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-771	Closed	-$184K	–	180
2021 Q4	$184K	Buy	+771	New	+$198K	0.09%	198

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

GraniteShares Advisors's BIIB Position: Q1 2022 in Review

GraniteShares Advisors sold out of Biogen (BIIB) in Q1 2022, closing a stake of 771 shares — an estimated $184K sold.

GraniteShares Advisors first reported a position in BIIB in Q4 2021 and held it in 1 quarter. The position peaked at $184K in Q4 2021. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

GraniteShares Advisors reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
GraniteShares Advisors sold 771 Biogen shares in Q1 2022, an estimated $184K.
GraniteShares Advisors first reported a position in Biogen in Q4 2021 and held it in 1 quarter.
GraniteShares Advisors's Biogen position peaked at $184K in Q4 2021.
951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on GraniteShares Advisors's 13F filing for Q1 2022, filed 6 May 2022.